CardioExchange Archive

April 21st, 2014

The CoreValve Trial: What Do You Say to Your Patients?

Harlan M. Krumholz, MD, SM

Harlan Krumholz presents a scenario based on the CoreValve trial and asks, “What do you say to your patient?”

---

March 13th, 2014

Achieving Consensus for the 2014 ACC/AHA Valvular Heart Disease Guideline

Catherine M. Otto, MD and Rick Akira Nishimura, MD

The writing committee co-chairs of the 2014 ACC/AHA Valvular Heart Disease Guideline discuss how the committee achieved consensus on the future treatment of valvular disease.

---

March 3rd, 2014

New Guidelines Issued for Valvular Heart Disease

Larry Husten, PHD

The American Heart Association and the American College of Cardiology today released new practice guidelines for the management of patients with valvular heart disease (VHD). Among its most notable features, the new document provides a new system of classification for VHD and lowers the threshold for interventions, including, for the first time, transcatheter as well […]

---

June 10th, 2011

TAVR: A Stroke of Genius or Bad Luck?

Richard A. Lange, MD, MBA and L. David Hillis, MD

After presentations at the ACC and American Association for Thoracic Surgery 2011 meetings, the PARTNER A results are finally published. PARTNER A compared  transaortic valve replacement (TAVR, also known as TAVI) with surgical aortic valve replacement (AVR) in patients with aortic stenosis who were eligible for AVR but considered to be at high surgical risk . At 1-year […]

---

June 5th, 2011

PARTNER A Results Published in NEJM

Larry Husten, PHD

Following its initial presentation at the ACC meeting in March, the results of PARTNER A have now been published online in the New England Journal of Medicine, in conjunction with a presentation at the Transcatheter Valve Therapies meeting in Vancouver. As reported previously, 699 high-risk older patients with severe aortic stenosis were randomized to either transcatheter aortic […]

---

May 12th, 2011

TAVI & Stroke: More Details Surface About PARTNER A

Larry Husten, PHD

In the past year transcatheter aortic valve implantation (TAVI) has emerged as a possible new treatment for patients with aortic valve disease who are not surgical candidates (the PARTNER B study) and for some patients as a viable alternative to surgery (the PARTNER A study). TAVI was found to be noninferior to surgery in the […]

---